Results 31 to 40 of about 60,286 (337)
Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]
, 2016 Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios +4 more
core +3 more sources
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]
, 2016 A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R +11 more
core +2 more sources
Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer [PDF]
, 2017 Purpose: Two previous single-arm trials have drawn conflicting conclusions regarding the activity of pazopanib in urothelial cancers after failure of platinum-based chemotherapy.
Alexander, Laura +17 more
core +2 more sources
Advances in targeted Alpha therapy for prostate cancer [PDF]
, 2019 BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G +11 more
core +2 more sources
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
New England Journal of Medicine, 2020 BACKGROUND The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer ...
R. Herbst +21 more
semanticscholar +1 more source
Liver Cancer, 2023 Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial.
M. Kudo +21 more
semanticscholar +1 more source
Liver Cancer, 2023 Introduction: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) vs sorafenib in the Phase III IMbrave150 study.
Masatoshi Kudo +10 more
doaj +1 more source
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab [PDF]
, 2017 Immune-checkpoint inhibitors represent the new standard of care in patients with advanced NSCLC who progressed after first-line treatment. This work aim to assess any difference in both efficacy and safety profiles among Nivolumab, Pembrolizumab and ...
Bazan, Viviana +6 more
core +1 more source
JAMA Oncology, 2023 This analysis of pooled data from 3 randomized clinical trials evaluates the association between immune-related adverse events and atezolizumab efficacy in patients with advanced non–small cell lung cancer.
M. Socinski +11 more
semanticscholar +1 more source
Respirology Case Reports, 2020 Atezolizumab is an immune checkpoint inhibitor (ICI) that is often associated with the development of several immune‐related adverse events, including fulminant type 1 diabetes mellitus (F1DM).
Toshihiko Nishioki +5 more
doaj +1 more source